The “cure” for preeclampsia is NOT delivery. Preeclampsia is an important signal for future cardiovascular complications once pregnancy is over. While there may not be a true “cure”, we do have options for chemoprophylaxis of preeclampsia. Currently, only low-dose aspirin is ACOG/SMFM endorsed for preeeclampsia prevention. But pravastatin is gaining steam. Pravastatin was previously classified (in the now discontinued FDA label) Category X. However, the FDA recently removed the warning regarding use of statins in pregnancy, resulting from the favorable data on pravastatin as a potential chemoprophylactic agent against preeclampsia. While short term fetal safety has already been documented, there was a gap in data regarding long-term neurodevelopmental outcomes in children exposed to this medication in- utero. But new data has some reassuring findings (with a CAVEAT). In this episode, we will highlight a soon-to-be released publication in the AJOG, which is the first to report on the long-term neuromotor, cognitive, and behavioral outcomes of children exposed to pravastatin in utero.